We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $1.8B
1-Year Est. Return 36.16%
This Fund
S&P 500
This Quarter Est. Return
+9.5%
1 Year Est. Return
+36.16%
3 Year Est. Return
+116.66%
5 Year Est. Return
+140.56%
10 Year Est. Return
+771.9%
AUM
$1.76B
AUM Growth
+$16.7M
Cap. Flow
-$84.9M
Cap. Flow %
-4.82%
Top 10 Hldgs %
24.37%
Holding
275
New
15
Increased
54
Reduced
181
Closed
13

Sector Composition

Rank Sector Weight
1 Healthcare 27.26%
2 Technology 26.93%
3 Industrials 17.12%
4 Consumer Discretionary 9.62%
5 Communication Services 6.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WNS
1
DELISTED
WNS Holdings
WNS
$56.7M 3.22%
609,098
-68,504
-10% -$5.97M
WWE
2
DELISTED
World Wrestling Entertainment
WWE
$47.1M 2.67%
515,573
-45,092
-8% -$3.86M
EEFT icon
3
Euronet Worldwide
EEFT
$2.77B
$46.6M 2.65%
416,332
-22,301
-5% -$2.41M
DOOR
4
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$45.2M 2.57%
497,941
-32,731
-6% -$2.88M
LRN icon
5
Stride
LRN
$3.48B
$45.1M 2.56%
1,149,825
-82,181
-7% -$3.22M
DFIN icon
6
Donnelley Financial Solutions
DFIN
$1.21B
$43.8M 2.49%
1,071,296
-97,188
-8% -$4.13M
ACIW icon
7
ACI Worldwide
ACIW
$5.81B
$41.2M 2.34%
1,526,081
-79,075
-5% -$2.09M
PBH icon
8
Prestige Consumer Healthcare
PBH
$2.35B
$35.8M 2.03%
571,263
-54,896
-9% -$3.43M
ZD icon
9
Ziff Davis
ZD
$1.92B
$34.5M 1.96%
442,372
-39,064
-8% -$3.2M
MEDP icon
10
Medpace
MEDP
$16B
$33.1M 1.88%
175,852
-22,399
-11% -$4.63M
PCRX icon
11
Pacira BioSciences
PCRX
$1.04B
$30.3M 1.72%
743,596
+306,311
+70% +$12.2M
SSTK icon
12
Shutterstock
SSTK
$195M
$26.6M 1.51%
366,346
-41,405
-10% -$2.9M
PINC
13
DELISTED
Premier
PINC
$26.3M 1.49%
811,342
-62,790
-7% -$2.06M
RVNC
14
DELISTED
Revance Therapeutics, Inc.
RVNC
$26.1M 1.48%
809,176
-66,320
-8% -$2.07M
DOCS icon
15
Doximity
DOCS
$3.75B
$25.5M 1.45%
786,032
+246,955
+46% +$8.19M
AGM icon
16
Federal Agricultural Mortgage
AGM
$2.38B
$25M 1.42%
187,686
-14,722
-7% -$1.93M
NGVT icon
17
Ingevity
NGVT
$2.48B
$23.7M 1.35%
331,729
-27,767
-8% -$2.2M
LCII icon
18
LCI Industries
LCII
$2.46B
$23.3M 1.32%
211,735
-19,378
-8% -$2.12M
APPS icon
19
Digital Turbine
APPS
$970M
$22.9M 1.3%
1,850,813
-23,675
-1% -$318K
AX icon
20
Axos Financial
AX
$5.69B
$22.8M 1.3%
617,821
-52,127
-8% -$2.25M
ARLO icon
21
Arlo Technologies
ARLO
$1.59B
$22.4M 1.27%
3,700,976
+568,457
+18% +$2.52M
LGND icon
22
Ligand Pharmaceuticals
LGND
$5.84B
$21.2M 1.2%
288,345
+2,711
+0.9% +$193K
RDWR icon
23
Radware
RDWR
$1.07B
$20.8M 1.18%
965,526
-25,690
-3% -$537K
SUPN icon
24
Supernus Pharmaceuticals
SUPN
$2.6B
$20M 1.13%
551,285
-68,042
-11% -$2.62M
AWI icon
25
Armstrong World Industries
AWI
$7.31B
$17.8M 1.01%
249,791
-14,189
-5% -$1.06M

Similar funds

Rice Hall James & Associates's Q1 2023 Portfolio in Review

As of Q1 2023, Rice Hall James & Associates held 275 positions worth $1.76B, up 0.96% from $1.74B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rice Hall James & Associates withdrew a net $84.9M in Q1 2023, closing 13 positions and reducing 181 holdings. Its most notable exit was IAA, Inc. Common Stock, an estimated $17.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 26% a quarter earlier, followed by Technology and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in RB Global worth $11.7M.

  • Rice Hall James & Associates's largest Q1 2023 buy was RB Global: 207,333 shares worth $11.7M.
  • Rice Hall James & Associates added most to Pacira BioSciences in Q1 2023, an estimated $12.2M increase.
  • Rice Hall James & Associates's biggest Q1 2023 reduction was Medifast, cutting an estimated $17.2M.
  • Rice Hall James & Associates fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $17.7M.
  • Rice Hall James & Associates's ten largest holdings make up 24% of its $1.76B portfolio in Q1 2023.
  • Rice Hall James & Associates opened 15 new positions and closed 13 in Q1 2023.
  • Rice Hall James & Associates's portfolio value rose 0.96% quarter-over-quarter to $1.76B.

Based on Rice Hall James & Associates's 13F filing for Q1 2023, filed 12 May 2023.